John M. Pagel, MD, PhD - Perspectives on Innovative Treatment for B-Cell Malignancies - a podcast by PVI, PeerView Institute for Medical Education
from 2020-10-22T18:00
Go online to PeerView.com/BUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading hematology-oncology experts discuss therapeutic innovations in a range of B-cell cancers, including chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL), and how community-based professionals can address the challenges of an increasingly complex B-cell cancer treatment landscape. The panel shares a series of practical insights on the continued validation and emergence of targeted therapy (such as BTK, BCL-2, PI3K, and EZH2 inhibitors) and other innovative options in diseases as diverse as CLL, MCL, FL, and DLBCL. Upon completion of this activity, participants should be better able to: Summarize the current treatment role of targeted therapies and other innovative agents across a range of B-cell cancer settings and patient populations, Cite updated safety and efficacy evidence on novel therapeutics, including single-agent and combination regimens, in patients with cancers such as CLL, FL, MCL, and DLBCL, Select personalized therapy with novel therapeutics for patients with treatment-naïve or relapsed/refractory B-cell cancers, Develop appropriate adverse event management strategies for patients with B-cell cancers who are experiencing toxicity while on therapy with newer therapeutics.
Further episodes of PeerView Oncology
Further podcasts by PVI, PeerView Institute for Medical Education